From left to right: Adam Koppel (Bain Capital Life Sciences), Mike Bozik (Knopp Biosciences CEO) and Clive Meanwell (Population Health)
July 12, 2022 07:01 AM EDT
Deals
Bioregnum

No sur­ren­der: A group of mar­quee biotech play­ers bets on the $350M PhI­II res­ur­rec­tion sto­ry of a heavy­weight con­tender

Any­one read­ing Bio­gen’s press re­lease on the flat fail­ure of dex­pramipex­ole in treat­ing ALS couldn’t over­look the note of fi­nal­i­ty then R&D chief Doug Williams …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times